JPM Healthcare Conference 2026 Redefining Molecular Diagnostics with Single-Molecule Precision 2 Disclaimer & Forward Looking Statement 2025 Q3 Business Update This presentation contains certain "forward-looking statementsˮ within the meaning of applicable securities laws. These statements relate to future events and results of BillionToOne, Inc. (the "Company,ˮ "we,ˮ "us,ˮ or "ourˮ) and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, p ...

BillionToOne (NasdaqGS:BLLN) Q3 2025 Earnings Call December 09, 2025 04:30 PM ET Company ParticipantsRoss Taylor - CFOCasey Woodring - Vice President of Equity ResearchOguzhan Atay - Co-founder, CEO, and Board ChairDavid Deichler - Head of Investor RelationsConference Call ParticipantsTycho Peterson - Managing Director and Senior Equity AnalystMark Massaro - Managing Director and Senior Equity Research AnalystDavid Westenberg - Managing Director and Senior Research AnalystBrandon Couillard - Managing Direct ...

Core Viewpoint - BillionToOne, a molecular diagnostics company, is set to raise $200 million through its IPO by offering 3.8 million shares priced between $49 and $55 per share, resulting in a fully diluted market capitalization of $2.7 billion at the midpoint of the proposed price range [1][2] Company Overview - Founded in 2016, BillionToOne focuses on prenatal screening and cancer treatment monitoring, utilizing its Quantitative Counting Templates technology to detect DNA molecules with single-base pair precision [2] - The company plans to list on NASDAQ under the ticker symbol BLLN, with joint bookrunners including JPMorgan, Jefferies, Wells Fargo Securities, and BTIG [2] Product Development - BillionToOne has developed a single-molecule next-generation sequencing (smNGS) platform for prenatal and oncology products, allowing significant insights through simple blood collection [1] - In 2019, the company launched its first prenatal product, UNITY, which is a non-invasive prenatal test for assessing the risk of recessive genetic diseases without requiring paternal samples or invasive procedures [1] - In 2023, BillionToOne introduced two complementary pan-cancer liquid biopsy tests: Northstar Select for guiding treatment choices and Northstar Response, a methylation-based test that quantifies cancer severity at the single-molecule level without tissue biopsy [1] Financial Performance - For the 12 months ending June 30, 2025, BillionToOne reported revenue of $209 million [2]

Core Insights - BillionToOne, a molecular diagnostics company, has filed for an IPO to raise up to $100 million [1][2] - The company focuses on developing prenatal and oncology diagnostic technologies using its single-molecule next-generation sequencing (smNGS) platform [1] Company Overview - Founded in 2016 and headquartered in Menlo Park, California, BillionToOne reported revenue of $209 million for the 12 months ending June 30, 2025 [2] - The company plans to list on the NASDAQ under the ticker symbol "BLLN" [2] Product Development - In 2019, BillionToOne launched its first prenatal testing product, UNITY, which is the world's first non-invasive prenatal testing technology based on cell-free DNA [1] - In 2023, the company introduced two complementary liquid biopsy products: Northstar Select for treatment guidance and Northstar Response, which quantifies cancer burden at the single-molecule level without tissue biopsy [1]